Page 461 - Binder2

Patients are not passive participants. They are stakeholders
in the biologic economy, and they deserve therapies that
last.

What the patient and advocacy world can do:

• Demand immune transparency. Ask for the
drug’s ADA rates. Its average time to SLOR. How
often patients switch off it in the real world. Push
for these metrics to be disclosed, just like side effect
profiles.
• Campaign for immune-informed access. Push
payers to prioritize shelf-stable, durable biologics.
Ask regulators to include immune compatibility in
their approval decisions.
• Tell the truth. Share stories not just of response—
but of rejection, switching, burden. The more
visible these patterns are, the harder they become to
ignore.
• Educate fellow patients. Help others understand
that immune rejection isn’t a moral failure or
personal defect—it’s a design flaw. And it’s fixable.

The movement will scale when patients stop accepting
planned obsolescence—and start demanding biological
endurance.

The Movement’s Thesis: Persistence is the New
Potency

Whether you’re a researcher in a lab, a founder pitching a
VC, or a patient tracking your biologic journey—the new
rallying cry is clear:

459